MedTrace Logo

Stemchymal® for Polyglutamine Spinocerebellar Ataxia

NCT06397274 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2024-05-02

No results posted yet for this study

Summary

The purpose of the clinical trial is to study the therapeutic efficacy and safety of Stemchymal® infusions for polyglutamine spinocerebellar ataxia treatment by a randomized, double-blind, placebo-controlled study design. Eligible subjects will receive Stemchymal® through intravenous infusion.

Conditions

  • Spinocerebellar Ataxias

Interventions

BIOLOGICAL

Stemchymal

Patients will receive Stemchymal® through intravenous infusion

BIOLOGICAL

Placebo

Patients will receive Placebo through intravenous infusion

Sponsors & Collaborators

  • Steminent US, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-06-01
Primary Completion
2028-06-01
Completion
2028-06-01
FDA Drug
Yes

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06397274 on ClinicalTrials.gov